SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RGLS, KRON, PPBI, COEP on Behalf of Shareholders

1. RGLS to be acquired by Novartis for $7.00 per share. 2. Shareholders will also receive contingent value rights based on regulatory approval. 3. Investor rights law firm investigating potential violations related to the deal. 4. RGLS shareholders might pursue legal options for increased transaction value. 5. Halper Sadeh LLC highlights corporate reforms and recovery for defrauded investors.

M&A

75

4m saved

Insight

Article

FAQ

Why Bullish?

The acquisition price of $7.00 per share represents a premium for shareholders, which is generally viewed positively. Historical events, like acquisitions in biotech, often lead to stock price appreciation, especially if the deal is perceived as fair and beneficial.

How important is it?

The article directly addresses RGLS's acquisition, which crucially affects shareholder value. The nature of legal investigations surrounding mergers highlights potential risks and legal recourse for shareholders, hence it warrants a significant importance score.

Why Short Term?

The immediate impact will be seen as the acquisition progresses and shareholders react to the offer. Once the regulatory approvals and contingent value rights are addressed, the impact may stabilize.

Related Companies

NVS

NEW YORK, May 6, 2025 /PRNewswire/ --

Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

Regulus Therapeutics Inc. (NASDAQ: RGLS)

's sale to Novartis AG. Under the terms of the proposed transaction, Regulus shareholders will receive $7.00 per share in cash and a contingent value right providing for payment of $7.00 per share, contingent upon the achievement of a milestone with respect to regulatory approval of Regulus' lead product candidate, farabursen. If you are a Regulus shareholder, click here to learn more about your rights and options.

Kronos Bio, Inc. (NASDAQ: KRON)

's sale to Concentra Biosciences, LLC for $0.57 in cash per share plus one non-tradeable contingent value right. If you are a Kronos shareholder, click here to learn more about your rights and options.

Pacific Premier Bancorp, Inc. (NASDAQ: PPBI)

's sale to Columbia Banking System, Inc. for 0.9150 of a share of Columbia common stock for each Pacific share. If you are a Pacific shareholder, click here to learn more about your rights and options.

Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP)

's merger with Z Squared Inc. If you are a Coeptis shareholder, click here to learn more about your legal rights and options.

Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders. We would handle the action on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected].

Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Halper Sadeh LLC
Daniel Sadeh, Esq.
Zachary Halper, Esq.
(212) 763-0060
[email protected]
[email protected]
https://www.halpersadeh.com

SOURCE Halper Sadeh LLP